Intervention
Elamipretide
Research Observatory
Evidence Update
Current evidence
In MMPOWER-3, elamipretide did not improve either prespecified primary endpoint—six-minute walk distance or total fatigue score—at 24 weeks in the overall primary mitochondrial myopathy population.
What changed
A later post-hoc analysis of the same MMPOWER-3 trial reported exploratory differences in six-minute-walk outcomes in some genetically and phenotypically defined subgroups. These findings add a hypothesis about which patients might warrant prospective study; they are not independent confirmation of elamipretide efficacy.
What did not change
The overall Phase 3 result remains negative. The post-hoc publication does not establish that elamipretide is effective in the broader primary mitochondrial myopathy population and does not supersede the original trial result.
Why it matters
The new context makes the future development question more specific: whether elamipretide should be tested prospectively in predefined genotype- or phenotype-enriched populations rather than treating primary mitochondrial myopathy as one heterogeneous group.
Main limitation
The potentially favorable signals come from retrospective analyses of small subgroups within a trial that was negative overall. Six-minute walk showed the clearest subgroup difference, while fatigue and other outcomes did not provide comparable confirmation.
Next proof
A prospectively designed and adequately powered study that predefines the relevant genotype or phenotype and tests clinically meaningful functional and patient-reported outcomes.
Summary
In MMPOWER-3, elamipretide did not improve either prespecified primary endpoint—six-minute walk distance or total fatigue score—at 24 weeks in the overall primary mitochondrial myopathy population.
Intelligence Take
The new context makes the future development question more specific: whether elamipretide should be tested prospectively in predefined genotype- or phenotype-enriched populations rather than treating primary mitochondrial myopathy as one heterogeneous group.
Limitations
The potentially favorable signals come from retrospective analyses of small subgroups within a trial that was negative overall. Six-minute walk showed the clearest subgroup difference, while fatigue and other outcomes did not provide comparable confirmation.